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The objective of this study was to quantify the direct medical resources used and the corresponding burden of
disease in the treatment of patients with schizophrenia. Because low-frequency administration (LFA) of risperidone
guarantees adherence during treatment intervals and offers fewer opportunities to discontinue, adherence and
persistence were assumed to improve, thereby reducing relapses of major symptoms.
A decision tree model including Markov processes with monthly cycles and a five-year maximum timeframe was
constructed. Costs were adapted from the literature and discounted at a 3% annual rate. The population is a
demographically homogeneous cohort of patients with schizophrenia, differentiated by initial disease severity
(mildly ill, moderately ill, and severely ill). Treatment parameters are estimated using published information for
once-daily risperidone standard oral therapy (RIS-SOT) and once-monthly risperidone long-acting injection (RIS-LAI)
with LFA therapy characteristics derived from observed study trends. One-year and five-year results are expressed as
discounted direct medical costs and mean number of relapses per patient (inpatient, outpatient, total) and are
estimated for LFA therapies given at three, six, and nine month intervals.
The one-year results show that LFA therapy every 3 months (LFA-3) ($6,088) is less costly than either RIS-SOT
($10,721) or RIS-LAI ($9,450) with similar trends in the 5-year results. Moreover, the model predicts that LFA-3 vs.
RIS-SOT vs. RIS LAI therapy will reduce costly inpatient relapses (0.16 vs. 0.51 vs. 0.41). Extending the interval to six
(LFA-6) and nine (LFA-9) months resulted in further reductions in relapse and costs.
Limitations include the fact that LFA therapeutic options are hypothetical and do not yet exist and limited
applicability to compare one antipsychotic agent versus another as only risperidone therapy is evaluated. However,
study results have quantified the potential health state improvements and potential direct medical cost savings
achievable with the development and use of LFA medication delivery technologies.Background
Illness relapse remains a primary clinical and economic
concern in the treatment of patients with schizophrenia. It
is associated with significant direct medical and societal
costs [1,2], increased illness symptomology and functional
deterioration [3], and a reduced patient [4] and care-giver
[5] quality of life. Patients who relapse experience as much
as a four-fold increase in costs compared to those who do
not relapse [1]. In the US, the direct medical expenditures
attributable to relapse exceed $22 billion with the cost of
inpatient care being the primary cost contributor [6-8].* Correspondence: nf@mdm-inc.com
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reproduction in any medium, provided the orRelapse occurrence is a multi-factorial problem. How-
ever, suboptimal medication adherence and/or persistence
are generally cited as a primary causative factor leading to
significant increases in resource utilization [9-11]. Con-
versely, optimizing medication compliance has been
shown to improve symptoms and decrease the frequency
and duration of hospital stays [11].
Prolonging the duration of action of an administered
agent with a resultant reduction in dosing frequency
represents one strategy for improving medication com-
pliance. Several delivery systems have been evaluated for
their ability to provide extended drug exposure including
extended/sustained-release oral formulations, depot
injections, various implant technologies and transdermaltd. This is an Open Access article distributed under the terms of the Creative
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(LAI) formulations of second generation antipsychotic
medications are available in the US for the treatment of
schizophrenia. Risperidone long-acting injection [13] is
administered every two weeks while paliperidone palmi-
tate extended-release injectable suspension [14] is admi-
nistered 1x/month. To date, the data regarding the effect
of the LAIs on relapse-related hospitalizations is equivo-
cal with some [15,16] but not all [17] reports suggesting
a reduction in the frequency and/or duration of relapse-
related hospital stays or resource utilization.
Given the generally positive clinical and economic
consequences of prolonging the duration of action of
antipsychotic agents, it is of interest to examine the po-
tential impact of an even greater prolongation of action
on illness relapse rates. Therefore, the objective of this
study was to quantify the resources (from a third party
payer perspective) used and the corresponding burden
of disease due to a projected reduction in relapse fre-
quency resulting from further improvements in medica-
tion compliance in patients with schizophrenia.
Methods
Overview
A decision tree model which branched to Markov pro-
cesses was constructed (Figure 1). The Markov processes
had monthly cycles and a five-year timeframe. Costs and
quality adjusted life years (QALYs) were discounted at a
3% annual rate. For verification purposes, the model was
developed separately in TreeAge 2009 and Microsoft
Excel 2010 and predicted results from each platform
were compared. Direct medical costs were derived from
published studies and applied on a per-setting basis:
stable in the community, relapse requiring an inpatient
bed, relapse not requiring an inpatient bed.
This study estimates potential cost savings of a hypo-
thetical delivery technology that prolongs the duration of
action of an antipsychotic medication thereby permitting
low frequency administration (LFA) antipsychotic therapy.
Costs include direct clinical resources consumed duringFigure 1 Model structure.routine interaction with healthcare professionals, during
relapses occurring in the outpatient setting, and during
relapses occurring in the inpatient setting.
Given the abundance of economic analyses for risperi-
done (RIS) [15,18,19] in the literature, RIS has been
chosen as the foundation of therapy for this model in gen-
eric standard oral therapy (RIS-SOT) and risperidone
long-acting injection (RIS-LAI) formulations. Therefore,
the base case model was populated with literature-based
rates of adherence and persistence for RIS-SOT and RIS-
LAI along with corresponding rates of relapse [20,21].
The following terms have been defined to facilitate the
analyses reported. A therapy with a “low frequency of
administration” is labeled “LFA” and is assumed to be
administered less frequently than currently available
treatments administered every 2 weeks. A number
appearing next to the LFA label indicates the frequency
of administration (i.e. LFA-3 indicates administration
every 3 months).“Interval” when referring to therapy ad-
ministration represents the time between scheduled
administrations of therapy. “Routine Care” describes
standard, recommended care for all patients with schizo-
phrenia such as regular physician visits and counseling
services. “Outpatient relapse” describes an increase in
utilization of resources by the patient without requiring
an inpatient stay in a hospital bed. “Inpatient relapse”
includes increased direct medical resource use in
addition to an inpatient bed plus other hospital
resources. “Step Down Care” describes a category of care
occupied by patients as they transition from an inpatient
stay back to routine care in the community.Assumptions
The following are the primary assumptions of the model:
1. Simulated patients are a homogeneous cohort of an
“average” patient with schizophrenia.
2. The baseline efficacy of each scenario is the same
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administration modes, therefore adherence and
persistence are driven by administration frequency
only.
4. Patients incur costs corresponding to “Routine Care”
at all times regardless of relapse status.Model parameters
Adherence
Medication adherence is defined as “the extent to which
a patient acts in accordance with the prescribed interval
and dose of a dosing regimen.” [22] For this study, ad-
herence values were taken from the literature for the
RIS-SOT and RIS-LAI products [21]. The base case
assumption is that patients will, by definition, be 100%
adherent to a therapy that is administered once and lasts
for an extended period when using the Less Frequent
Administration options.Persistence
Medication persistence is defined as “the duration of the
time from initiation to discontinuation of therapy.” [22]
Because schizophrenia is a chronic illness and pharmaco-
logical therapy is a fundamental component of ongoing
care, we operationalized persistence as the proportion of
patients who discontinued their medications. Specifically,
persistence is estimated using reported rates of discon-
tinuation in CATIE phase I for risperidone [20]. Of the
four mutually exclusive reasons for discontinuation
reported in CATIE phase I, this study relies on all but the
adverse event rate, given that the base compound is the
same for all scenarios (RIS) regardless of administration
















scount rate (costs)Consequently, the rates of persistence differ by those
reported in CATIE phase I [20] in the following manner:
DAC = risperidone “All Cause” discontinuation reported
in CATIE phase I
DAE = risperidone discontinuation due to “Adverse
Events” reported in CATIE phase I
DPD = risperidone discontinuation due to the “Patient’s
Decision” reported in CATIE phase I
RIS-SOTPERS = 1.0 – (DAC – DAE)
LFAPERS = 1.0 – DPD
It is assumed that as the frequency of administration
decreases (at the same effectiveness), the more likely it
would be that a patient would discontinue based solely
on their decision. Therefore, the discontinuation rate for
an LFA therapy is assumed to be equal to the patient-
decision rate from CATIE [20].
Relapse rates
Rates of relapse given adherence for all treatments are
based on a published risperidone model [15] with a fixed
proportion occurring in the inpatient setting derived
from the same model [15]. A complete list of base case
inputs is shown in Table 1.
Resource use
Nicholl et al [19] published a database analysis compa-
ring the resource use between newly diagnosed schizo-
phrenia patients and chronic patients. Most of the unit
costs of resource components found in input Table 2
were derived using Nicholl et al [19]. Inpatient and out-
patient costs were derived using weighted averages of
the new and chronic patients. (Table 2) There was
complete overlap of the categories included in the
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for most resources. Once derived, total mean expendi-
tures for a category were then divided by the derived per
unit cost to populate the resource used. When categories
between inpatient and outpatient resources did not over-
lap, the unit costs and number of units were derived
using inpatient resources consumed for recently diag-
nosed patients compared to chronic patients.
The values in Table 2 that were derived from sources
other than Nicholl et al. are cost per day of hospitalization,
the number of days per inpatient stay, and the added cost
of step-down care after inpatient relapse. Cost of
hospitalization and number of days were derived from
2009 AHRQ HCUP data based on using a primary diagno-
sis of “Schizophrenia and other psychotic disorders” [25].
Step-down care as listed in Table 2 is assumed to take
place for one month at $40 per day based upon a study of
community mental health treatment services in 5 cities
across the U.S. [26].
Results
Base case
Base case results are presented in Table 3 and Table 4
for one-year and five-year timeframes, respectively. The
one-year results show that LFA (3 month) is less costly
than either RIS-SOT or RIS-LAI. Moreover, the model
predicts that LFA therapy will reduce inpatient and total
relapses in the first year compared to both RIS-SOT and
RIS-LAI therapies. These results suggest that cost offsets
due to reduction of inpatient relapses for LFA potentially
take effect in year one. The five-year base case results
comparing RIS-SOT, RIS-LAI, and LFA are shown in
Table 4. Similar to the one-year results, increasing
adherence and persistence through LFA therapy leads to
lower total costs and an appreciable reduction in
relapses over 5 years.Table 2 Resource units and costs
Resource Use Inp
Resource Cost Units per Outpatient Re
Room and Board $751 [25] 0.0
Medications $257 0.0
Step down care $40 [26] 0.0
Lab Tests $26 1.0
ER $425 1.0
Intensive Care $194 0.0
Devices $71 0.0
Psychotherapy $110 0.0
Physician Visits $70 0.0
Other While Stable $1,701 0.0
Other While Inpatient Relapse $2,379 0.0
All values from Nicholl et al. [19] except where noted; *= assumption. All costs updated
[27].Sensitivity analysis
One way sensitivity analysis was performed on variables
in the model by varying base case parameters by ±50%.
Major drivers of costs identified were the relapse rate
when non-adherent, the cost per inpatient relapse, and
the proportion of relapses requiring an inpatient stay
(data not shown).
Sensitivity analysis on administration frequency was
performed to quantify the impact of decreasing adminis-
tration frequency on health and economic outcomes. In
general, the trend of lower costs with fewer relapses
observed in the base case continued as administration
frequency decreased.
Discussion
The objective of this study was to predict the health and
economic impact of employing technologies that im-
prove medication compliance by extending drug delivery
and decreasing frequency of administration. The study
was based on the hypothesis that improving medication
compliance will lead to a reduction in illness relapse and
the costs associated with treating the relapses. Modeled
and clinical support for this hypothesis exists in the
published literature [6,9,15,16,21,23,28]. The model
used for the presented analysis implements information
for risperidone available in the public domain as a basis
for forward-thinking analysis. The results estimate the
value of seeking opportunities to reduce illness relapse
in this patient population.
Health states
Most published data support the hypothesis that
prolonging the duration of action of an antipsychotic
medication (with a resultant reduction in dosing fre-
quency) is associated with a reduction in schizophrenia
symptom exacerbation compared to standard oralut Table [19]












to 2011 costs using Bureau of Labor and Statistics Medical component of the CPI
Table 3 One-year base case model results (Mean values of the modeled population)
RIS-SOT RIS-LAI LFA −3 LFA −6 LFA −9
Direct Medical Costs (Discounted) Routine Care Costs $4,013 $4,013 $4,013 $4,013 $4,013
Inpatient Costs $6,508 $5,276 $2,013 $1,642 $1,398
Outpatient Costs $199 $161 $62 $50 $43
Total Direct Medical Costs $10,721 $9,450 $6,088 $5,706 $5,454
Health States Inpatient Relapses 0.51 0.41 0.16 0.13 0.11
Outpatient Relapses 0.45 0.36 0.14 0.11 0.10
Total Relapses 0.96 0.77 0.30 0.24 0.21
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weekly injectable formulation of risperidone reduced the
number of relapses per person by 0.2 while, at five years,
0.56 relapses were avoided. The one year reduction in
the present analysis is somewhat less than the prediction
of 0.6 relapses avoided in a model published by Edwards,
et al. [15] and the precise explanation for the difference
is unknown. However, the Edwards model predicted a
greater number of relapses for both the standard oral
therapy and long-acting injectable groups which may
have been a contributing factor. Conversely, the five year
projection in our model of 0.56 relapses avoided is con-
sistent with data presented by multiple models [21].
At present, there are no long-acting formulations of
antipsychotic therapy for schizophrenia with dosing
frequencies that extend beyond one month. Moreover,
there are no long-acting formulations of risperidone that
have dosing frequencies of greater than two weeks. None-
theless, given the application of existing technologies for
prolonging the duration of action of pharmaceutical
agents for up to one year in other therapeutic areas, it was
of interest to estimate the potentially beneficial effects of
applying these technologies to the treatment of schizo-
phrenia. Extending the duration of action to three months
was associated with further reductions in the number of
relapses compared with both standard, daily risperidone
therapy (RIS-SOT) as well as the currently available rispe-
ridone long-acting injection (RIS-LAI). Further improve-
ments were seen when the duration of action was
extended to six and nine months. Quantified estimates of
reductions in relapse produced in this study represent the
value of the study methodology and provide evidenceTable 4 Five-year base case model results (Mean values of th
Direct Medical Costs (Discounted) Routine Care Costs
Inpatient Costs
Outpatient Costs
Total Direct Medical Costs
Health States Inpatient Relapses
Outpatient Relapses
Total Relapsessupporting the potential therapeutic benefit of extending
the duration of action of antipsychotic medications be-
yond that which is currently available.Costs
Because relapse is a primary cost driver in the manage-
ment of schizophrenia, it is anticipated that a reduction
in relapses would be associated with corresponding
reductions in the cost of treatment. This association has
been reported in the literature [8,28] and is confirmed in
the current model. At one year, total direct medical costs
were greatest for daily, standard therapy and decreased
with increasing duration of action.
In our analysis, improving medication compliance by
prolonging duration of action and reducing administra-
tion frequency from daily to once every two weeks
resulted in a reduction in direct medical costs of almost
$1300/patient at the end of one year. The cost reduction
seen when comparing the Less Frequent Administration
(LFA) options (> 3 months) to RIS-SOT was even more
substantial, resulting in cost reductions ranging from
$4600 to $5300 per patient. The LFA options also
demonstrated cost reductions versus the bi-weekly ris-
peridone injection with the 3-, 6-, and 9-month alterna-
tives reducing costs by $3300/patient, $3700/patient,
and $4000/patient, respectively. Importantly, most of the
reduction in direct medical costs was produced via a re-
duction in the costs associated with inpatient care. A
sensitivity analysis confirmed the central contribution of
relapses requiring inpatient hospitalization to direct
medical costs associated with managing schizophrenia.e modeled population)
RIS-SOT RIS-LAI LFA - 3 LFA −6 LFA −9
$18,326 $18,326 $18,326 $18,326 $18,326
$42,419 $38,721 $26,241 $25,251 $24,261
$1,299 $1,185 $803 $773 $743
$62,043 $58,232 $45,370 $44,349 $43,329
3.52 3.22 2.20 2.12 2.04
3.12 2.85 1.95 1.88 1.81
6.63 6.07 4.15 4.00 3.85
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the societal burden of disease from the base case model
were performed using US population data from the 2010
census [29] and the prevalence of schizophrenia data
from the National Institute of Mental Health [30]. The
incremental difference between RIS-SOT and RIS-LAI
was estimated to be a savings of $4.3 billion; extending
the frequency of administration to nine months resulted
in estimated savings of $17.8 billion compared to RIS-
SOT. Base case total burden was found to be consistent
with previously published estimates [7].
In this study, we were limited by the fact that risperidone-
based therapeutic options with dosing frequencies of greater
than two weeks do not exist. While this limitation may have
impacted our assumptions concerning the persistence of
therapy with the LFA options, it should not have influenced
the adherence levels. Assuming that less frequent dosing will
be accomplished via utilization of a long-acting injection or
implantation of a drug or drug-device combination, once
administered, adherence will be 100% for the identified dos-
ing period. The fact that these longer duration alternatives
do not exist in schizophrenia also impacts the total absolute
costs and cost differentials as we were not able to include
“cost of therapy” in our total direct medical cost calculations.
This study is also limited in its applicability to com-
pare the potential benefits of utilizing one antipsychotic
agent versus another as we assumed the use of risperi-
done in all dosing scenarios. However, we believe that
restricting our model to one molecule eliminates the
potential confounding that might occur as a result of dif-
ferences in safety/tolerability and efficacy that might be
seen when two different molecules are compared.
There are many potentially fertile areas for future re-
search including an opportunity to further evaluate both
the clinical and economic consequences of improved
medication adherence and persistence in patients with
schizophrenia. More data is required to determine the
most effective combination of drug delivery mechanism
and dosing frequency for optimal disease management.
From an economic perspective, the societal costs asso-
ciated with schizophrenia are well-documented. How-
ever, it will be of great interest to predict the potential
impact of a new treatment option not only on direct
medical costs but also on the larger societal burden.
Conclusion
This study quantifies the impact of medication adher-
ence and persistence on illness relapse occurrences in
patients with schizophrenia. In addition, it demonstrates
the potential health state improvements and direct med-
ical cost savings that might be realized from the develop-
ment of medication delivery technologies that prolong
the duration of action of antipsychotic agents beyond
that which is currently available.Competing interests
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